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Abstract
Background: Breast cancer studies frequently focus on the role of the tumor microenvironment in the promotion of 
cancer; however, the influence of the normal breast microenvironment on cancer cells remains relatively unknown. To 
investigate the role of the normal breast microenvironment on breast cancer cell tumorigenicity, we examined 
whether extracellular matrix molecules (ECM) derived from premenopausal African-American (AA) or Caucasian-
American (CAU) breast tissue would affect the tumorigenicity of cancer cells in vitro and in vivo. We chose these two 
populations because of the well documented predisposition of AA women to develop aggressive, highly metastatic 
breast cancer compared to CAU women.
Methods: The effects of primary breast fibroblasts on tumorigenicity were analyzed via real-time PCR arrays and 
mouse xenograft models. Whole breast ECM was isolated, analyzed via zymography, and its effects on breast cancer 
cell aggressiveness were tested in vitro via soft agar and invasion assays, and in vivo via xenograft models. Breast ECM 
and hormone metabolites were analyzed via mass spectrometry.
Results: Mouse mammary glands humanized with premenopausal CAU fibroblasts and injected with primary breast 
cancer cells developed significantly larger tumors compared to AA humanized glands. Examination of 164 ECM 
molecules and cytokines from CAU-derived fibroblasts demonstrated a differentially regulated set of ECM proteins and 
increased cytokine expression. Whole breast ECM was isolated; invasion and soft agar assays demonstrated that 
estrogen receptor (ER)-, progesterone receptor (PR)/PR- cells were significantly more aggressive when in contact with 
AA ECM, as were ER+/PR+ cells with CAU ECM. Using zymography, protease activity was comparatively upregulated in 
CAU ECM. In xenograft models, CAU ECM significantly increased the tumorigenicity of ER+/PR+ cells and enhanced 
metastases. Mass spectrometry analysis of ECM proteins showed that only 1,759 of approximately 8,000 identified were 
in common. In the AA dataset, proteins associated with breast cancer were primarily related to tumorigenesis/
neoplasia, while CAU unique proteins were involved with growth/metastasis. Using a novel mass spectrometry 
method, 17 biologically active hormones were measured; estradiol, estriol and 2-methoxyestrone were significantly 
higher in CAU breast tissue.
Conclusions: This study details normal premenopausal breast tissue composition, delineates potential mechanisms 
for breast cancer development, and provides data for further investigation into the role of the microenvironment in 
cancer disparities.
Background
Breast cancer is the most frequently diagnosed cancer
and the second leading cause of cancer-related deaths of
women living in the US [1]. Breast cancer manifests itself
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in the mammary epithelium; however, tumors do not
progress to malignancy in isolation. The local microenvi-
ronment can enhance or suppress tumor growth and pro-
gression, as well as metastases [2-8]. The stroma is
composed of diverse cell types including endothelial and
immune cells, adipocytes, and fibroblasts. These cells
secrete products, including growth factors and extracel-
lular matrix (ECM) components, which profoundly affect
cell behavior. It has been suggested that altered commu-
nication between these cells can lead to the progression
or expansion of malignant growth. While numerous stud-
ies have observed the effects of synthetic or mouse-
derived ECM on breast cancer cells, relatively little is
known about the molecular interactions between human
breast ECM and epithelial cells.
Recently, a novel in vivo xenograft model mimicking
human ductal carcinoma in situ (DCIS) illustrated that
the progression of normal tissue towards a neoplastic
state depends on the surrounding stromal cells [9]. Nor-
mal myoepithelial cells inhibited the progression of DCIS
to an invasive carcinoma, while the addition of fibroblasts
enhanced invasion. Additionally, reports demonstrated
that the mammary microenvironment can reprogram
both embryonic and adult murine stem cells into mam-
mary cells capable of expressing milk proteins and hor-
mone receptors, substantiating the remarkable control
the environment has on cell behavior [10,11].
African-American (AA) women have a lower overall
incidence of breast cancer compared to Caucasian-Amer-
ican (CAU) women but a significantly higher incidence
rate before the age of 40, and a higher mortality rate at
any age [1]. Breast carcinomas in premenopausal AA
patients are more often triple negative, which lack estro-
gen receptor (ER), progesterone receptor (PR), and
human epidermal growth factor receptor 2 (HER2)
amplification [12-15]. Triple-negative cancers constitute
one of the most challenging types of breast cancer, as the
only systemic therapy is chemotherapy.
It has been proposed that premenopausal AA women
develop triple-negative tumors due to multifactorial dif-
ferences including socioeconomic factors, body mass
index, diet, earlier age at first pregnancy, lower incidence
of breastfeeding, and higher breast density [16,17]. How-
ever, these factors do not explain everything. A recent
study reported that even after adjusting for socioeco-
nomic status, AA women still have a 22% higher mortal-
ity rate [18]. Interestingly, there are parallels in carcinoma
development between women in western African nations
and AAs, including early onset of disease and hormone
receptor negativity [19]. These women share common
ancestry suggesting that mutations in breast cancer sus-
ceptibility genes are partly responsible for the high preva-
lence of triple-negative carcinomas [19]. This
predisposition of AA women to develop a more aggres-
sive cancer compared to CAU women provides a unique
model for studying the role of the normal breast microen-
vironment on breast cancer development. Hence, our
objective was to determine whether factors within the
local microenvironment of premenopausal AA and CAU
women differentially alter the behavior of breast cancer
cells.
In this study, premenopausal AA or CAU primary
breast fibroblasts and ECM from whole breast tissue were
isolated and examined by several in vitro and  in vivo
methods. ER-/PR- cells were significantly more aggressive
in the presence of AA ECM by both invasion and soft
agar assays; in contrast, CAU ECM caused increased
aggressiveness with ER+/PR+ cells. By mass spectrometry,
approximately 22% of identified proteins were common
to both AA-derived and CAU-derived ECM; proteins
related to tumorigenesis/neoplasia were more highly
associated with the AA ECM while proteins involved
with growth/metastasis were more prevalent with the
CAU ECM. Using a novel mass spectrometry assay to
measure biologically active hormones, only estradiol, est-
riol, and 2-methoxyestrone levels were significantly
higher in the CAU breast. Finally, in a xenograft model,
CAU ECM significantly enhanced the tumorigenicity and
metastases of ER+/PR+ cells. T o our knowledge, we are
the first to investigate the normal ECM of premenopausal
women; furthermore, results from this study may help
identify mechanisms by which AA are predisposed to
developing a more aggressive breast cancer.
Methods
Collection and processing of patient samples
Collection of patient samples was performed in accor-
dance with the guidelines of the National Cancer Institute
Review Board, under four separate approved protocol
numbers OH99-C-NO57, 02-C-0077E, 04-C-0199, and
OHSR4789. Written informed consent was obtained
from all human subjects as stipulated in the protocols.
Breast tissue was collected from fasting, age-matched,
premenopausal AA or CAU reduction mammoplasty
patients. The tissue obtained for analyses was considered
pathological medical waste; thus any clinical details of the
women, apart from age and race, were unattainable.
Overall, 53 AA and 50 CAU breast tissue samples, from
patients with a median age of 29 years, were used for
analyses. Race was self-reported by the patients. Tissue
was collected from southern, eastern, and midwestern
regions of the US. A pathologist confirmed that each
patient was free of malignant or hyperplasic growth.
Immediately after surgery a separate piece of tissue was
used for isolation of primary human breast fibroblasts,
and the remaining tissue was snap frozen and stored at -
80°C for RNA and protein analyses, and for ECM isola-
tion.Fleming et al. BMC Medicine 2010, 8:27
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Pleural effusion cells were collected from a parous, 49-
y ea r - o l d  C a u cas i a n  b r eas t  ca n c e r  pa t i e n t  wi t h  a n  E R +/
PR+, Her2-, T1, pN1, M1, Grade 3, poorly differentiated
invasive ductal carcinoma. Immediately following collec-
tion, cells were processed as follows: cells were gently pel-
leted by centrifugation, washed twice in Hank's buffered
saline solution, frozen viably in dimethylsulfoxide
(DMSO) Freeze media (Invitrogen; Gaithersburg, MD,
USA) and stored in liquid nitrogen until used. The cells
derived from the pleural effusion were ER-/PR- and Her2-,
as determined by immunohistochemistry.
Fluorescent activated cytometric sorting (FACS)
Immediately prior to use, pleural effusion cells were
stained with lineage markers to segregate tumor from
non-tumor cells as previously described [20]. Briefly, lin-
eage marker antibodies used were fluorescein conjugated
anti-human CD2, CD3, CD10, CD16, CD18, CD31,
CD64, and CD140b (BD Biosciences, San Jose, CA, USA).
Cells were stained in a phosphate-buffered saline (PBS)
solution containing 0.1% fetal bovine serum (FBS) and
100 units/ml penicillin/streptomycin for 25 min at 4°C.
Cell sorting was performed on a BD FACSAria operating
at low pressure (20 psi) using a 100 μm nozzle. Doublets
were electronically gated out and 7-aminoactinomycin D
(7AAD, 1 μg/ml final concentration, BD Biosciences) was
used for live/dead cell distinction. Live, fluorescein nega-
tive tumor cells were sorted into a PBS solution contain-
ing 50% FBS. Post-sort analysis typically indicated
purities of >96% with minimal cell death (<10%). FACS
data were analyzed using FlowJo v8.7.3 (TreeStar, Ash-
land, OR, USA).
Cell culture
MCF10Ca1h cells (kind gift of FR Miller, Wayne State
University, Detroit, MI, USA, through LM Wakefield,
Center for Cancer Research (CCR), National Cancer
Institute (NCI), Bethesda, MD, USA) were maintained as
described previously [21]. All other cell lines were
obtained from the American Type Culture Collection
(ATCC; http://www.atcc.org) and cultured according to
the repository's instructions. Fibroblasts were isolated as
described [22]. Briefly, <5 mm pieces of tissue were
placed on a scratched cell culture dish. Tissue pieces were
covered with a minimal amount of media and, with time,
the fibroblasts crawled out of the tissue to form a mono-
layer on the dish. The fragments of tissue were removed
and the remaining fibroblasts were passaged and plated
as monolayer cultures to expand and ensure fibroblast
purity. When necessary, epithelial cells were separated
from the stromal cells by differential trypsinization and
selective pressure with fibroblast growth medium. Fibro-
blasts were grown for a maximum of two passages prior
to analysis.
Isolation of whole breast tissue ECM proteins
Extraction of human breast ECM from whole breast tis-
sue was performed as previously described [23]. A mini-
mum of three different age-matched patient samples per
treatment group was used for each extraction (total n =
26 AA, and 21 CAU). Pools were necessary in order to
obtain enough tissue from which to extract ECM. A dif-
ferent pool of samples was used for each experiment.
Matrices were stored on ice at 4°C and used within 5 days
of isolation.
Zymography
Equal amounts of protein were separated by gel electro-
phoresis in a 10% Tris-glycine polyacrylamide gel (Invit-
rogen) with 0.1% gelatin incorporated as a substrate.
Proteins were renatured, soaked in developing buffer, and
then stained according to the manufacturer's instruc-
tions. Matrix metalloproteinase (MMP) activity was visu-
alized as clear bands against a dark blue background
where the protease has digested the substrate. Identifica-
tion of MMPs was based on published molecular weights.
Three independent experiments, each with different
pools of age-matched patient samples (minimum of three
patient samples per pool), were performed with each
individual experiment repeated in duplicate to ensure
repeatability.
Invasion assay
Transwell membranes (8 μm pores) were precoated with
equal amounts of ECM, adjusted for total protein con-
tent. Breast cancer cells were washed, resuspended in
serum-free medium, and then plated in the top chamber
of transwell inserts (at the predetermined concentration
f o r  e a c h  c e l l  l i n e ) .  T h e  c e l l s  w e r e  a l l o w e d  t o  i n v a d e
through the membrane for up to 16 h towards FBS-con-
taining medium in the bottom chamber. Following inva-
sion, the cells were wiped from the top surface of the
membrane; the remaining cells were fixed in methanol
and stained with a 1% toluidine blue solution. Four inde-
pendent experiments, each with different pools of patient
samples (minimum of three patient samples per pool),
were performed with each individual experiment
repeated in duplicate to ensure repeatability.
Soft agar assay
Breast cancer cells were plated on an 0.66% agarose base
in a 0.33% top soft agar layer in 35 mm cell culture dishes
with the addition or absence of 100 μl of ECM, adjusted
for equal protein content. Cells were incubated for 10 to
12 days, and then stained overnight with nitrobluetetra-
zolium. The total number of colonies in each dish was
counted using the AccuCount 1000 colony counter (Bio-
Logics, Manassas, VA, USA); however, only colonies over
1 μm in diameter were included in the calculation. Three
independent experiments, each with different pools ofFleming et al. BMC Medicine 2010, 8:27
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patient samples (minimum of three patient samples per
pool), were performed with each individual experiment
repeated in duplicate to ensure repeatability.
Immunohistochemistry
Immunohistochemistry was performed with appropriate
controls as described previously [24]. Briefly, sections of
formalin fixed, paraffin embedded tissue 5 μm thick were
prepared from all tumors obtained in the xenograft stud-
ies, and fragments of the lungs and livers of animals used
in the metastasis experiments. The human specific
COXIV antibody (1:1,000, Cell Signaling; Boston, MA,
USA) was used for detection of metastases of breast can-
cer cells in the xenograft experiments. Antibodies Ki67
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) and
ER (Leica Microsystems, Bannockburn, IL, USA) were
used according to manufacturers' instructions. Staining
was performed using Vectastain ABC kit (Vector Labora-
tories; Burlingame, CA, USA) according to the manufac-
turer's instructions. Color was developed with
diaminobenzidine peroxidase substrate kit (Vector Labo-
ratories) and sections were counterstained with hematox-
ylin.
Quantitative real-time (qRT) PCR and PCR arrays
Total RNA was isolated from primary breast fibroblasts
using the Qiagen RNeasy kit according to the manufac-
turer's instructions (Valencia, CA, USA). RNA was
reverse transcribed using MMLV reverse transcriptase
(Invitrogen) and primed with oligo-dT and random hex-
amers (Invitrogen). The cDNA was subjected to RT-PCR
amplification using gene specific primers and 2 × Brilliant
II Sybr Green QPCR Mastermix (Stratagene, La Jolla, CA,
USA). Primer sequences are given in Additional file 1:
Table S1. Quantitative RT-PCR was analyzed via the
ΔΔCT method, and PCR products were visualized by
agarose gel electrophoresis. qRT-PCR arrays were per-
formed and analyzed with the commercially available
qRT-PCR array kits according to the manufacturer's
instructions (SABiosciences, Frederick, MD, USA). Three
pools of fibroblasts, each with a minimum of three differ-
ent patient fibroblasts per pool, were used for each array
(n = 9 AA and 10 CAU). Validation of the array data used
different, freshly isolated individual primary fibroblasts
(n = 9 AA and 9 CAU).
In vivo tumor formation assays
Animal experiments were conducted in accord with
accepted standards of humane animal care and approved
by the Animal Care and Use Committee at the National
Institutes of Health, USA. Female, 8-week-old athymic
Nu/Nu mice, or NOD/SCID where indicated, were ran-
domized into three groups with a minimum of five mice
per group (APA, Frederick, MD, USA). Mice were anes-
thetized by an intraperitoneal injection of ketamine/xyla-
zine (750 and 50 mg/kg body weight, respectively) in
Hank's buffered saline solution (HBSS) prior to surgically
exposing the gland for injection. NOD SCID mice were
supplemented with estrogen via a subcutaneous pellet
(0.72 mg β-estradiol, 90-day release, Innovative Research
of America, Sarasota, FL, USA) at the time of breast can-
cer cell injection. For fibroblast studies, mouse abdominal
mammary glands were humanized with primary human
fibroblasts as previously described [25]. Each experiment
used a minimum of three different patient pools of fibro-
blasts per humanization (total AA n = 12, CAU n = 14).
Following humanization, primary metastatic breast can-
cer cells, derived from a pleural effusion, were sorted via
FACS to remove non-epithelial cells, and then mixed with
1:1 ratio of 1 × PBS:Matrigel (BD Biosciences). A total of
30 μl of ECM containing 5 × 103 cells was injected into
the humanized abdominal mammary gland fat pad.
Tumor growth was measured using calipers on a weekly
basis. Tumors were excised when the majority of tumors
reach 1.0 cm3, and final tumor volume was calculated
((0.5 × L) × (0.5 × W) × (0.5 × H) × (4/3) × (π)).
For ECM studies, breast cancer cells (MDA-MB-231
and T47D) proliferating in log phase were mixed with
control matrix (Matrigel), AA or CAU ECM, adjusted for
equal protein content. A total of 40 μl of ECM containing
1 × 106 or 2 × 106 cells was injected, respectively, into the
abdominal mammary fat pad or subcutaneously proximal
to the scapula. Tumor growth was measured on a weekly
basis using calipers. Tumors were excised using survival
surgery when the majority of tumors reach 1.0 cm3, and
final tumor volume was calculated. At 3 months post
tumor excision, the animals were killed and the liver and
lung tissues were removed for detection of metastases.
Tissues were analyzed for metastases by pathological
evaluation, quantitative PCR using human-specific prim-
ers developed to β2-microglobulin [26], and immunohis-
tochemistry using a human specific COXIV antibody.
Each animal experiment was repeated a minimum of two
times, using different pools of ECM (minimum of three
patients per pool) for each experiment.
Mass spectrometry
Three sets of pools of AA and CAU ECM, derived from
different patients in each pool, minimum of three
patients per pool, were quantified and 2 μg of ECM from
each pool were separated on a 4% to 12% Nu-PAGE Bis-
Tris gel in MOPS SDS running buffer (Invitrogen). The
gel was washed and stained using SimplyBlue Safe Stain
Solution (Invitrogen). Each gel lane was divided into 10
sections, excised, destained, lyophilized and digested
with trypsin in 25 mM NH4HCO3, pH 8.4, overnight at
37°C. The tryptic peptides were extracted from gel slices
using 70% acetonitrile containing 5% formic acid, lyo-
philized, and the peptides reconstituted in 0.1% formicFleming et al. BMC Medicine 2010, 8:27
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acid prior to nanoflow reversed-phase liquid chromatog-
raphy (nanoRPLC) mass spectrometry analysis. NanoR-
PLC columns were slurry packed with 5 μm, 300 Å pore
size C-18 silica-bonded stationary reverse-phase particles
(Jupiter; Phenomenex, Torrance, CA, USA) in a 75 μm
internal diameter × 10 cm fused silica capillary with a
flame pulled tip. The column was connected to an Agi-
lent 1100 nanoLC system and coupled to a linear ion trap
(LIT) mass spectrometer (LTQ, ThermoElectron, , San
Jose, CA, USA, operated with Xcalibur 1.4 SR1 software).
The samples were injected onto the column and the pep-
tides eluted using a gradient of mobile phase A (0.1% for-
mic acid in water) and B (0.1% formic acid in
acetonitrile). The LTQ was operated in a data-dependent
mode in which the seven most abundant peptide molecu-
lar ions in every MS scan were sequentially selected for
collision-induced dissociation (CID) using a normalized
collision energy of 35%. Dynamic exclusion was applied
to minimize repeated selection of peptides previously
selected for CID.
Tandem mass spectra were searched against the Uni-
Prot human proteomic database from the European Bio-
informatics Institute with SEQUEST (http://fields.
scripps.edu/sequest/) operating on a 40-node Beowulf
cluster. Peptides were searched using fully tryptic cleav-
age constraints. Oxidation of methionine (+15.9949 Da)
was included as dynamic modification. For a peptide to
b e  c o n s i d e r e d  l e g i t i m a t e l y  i d e n t i f i e d ,  i t  m u s t  h a v e
achieved a minimum Δ correlation (ΔCn) of 0.08 and
charge state-dependent cross correlation (Xcorr) scores
of 1.9 for [M + H]1+, 2.2 for [M + 2H]2+, and 3.1 for [M +
3H]3+ peptide molecular ions. Data were subjected to
functional analysis through the use of Ingenuity pathways
analysis (IPA; Ingenuity Systems, http://www.ingenu-
ity.com) and BIOBASE (http://www.biobase-interna-
tional.com).
Estrogen metabolite analysis
Reagents and materials for steroid analysis
A total of 15 estrogens including estrone (E1), estradiol
(E2), estriol (E3), 16-epiestriol (16-epiE3), 17-epiestriol
(17-epiE3), 16-ketoestradiol (16-ketoE2), 16α-hydroxye-
strone (16α-OHE1), 2-methoxyestrone (2-MeOE1), 4-
methoxyestrone (4-MeOE1), 2-hydroxyestrone-3-methyl
ether (3-MeOE1), 2-methoxyestradiol (2-MeOE2), 4-
methoxyestradiol (4-MeOE2), 2-hydroxyestrone (2-
OHE1), 4-hydroxyestrone (4-OHE1), and 2-hydroxyestra-
diol (2-OHE2) and 2 androgens, androstenedione and tes-
tosterone, were obtained from Steraloids (Newport, RI,
USA). Stable isotope labeled steroids, including estradiol-
13,14,15,16,17,18-13C6  (13C6-E2) and estrone-13,14,15,
16,17,18-13C6 (13C6-E1) were purchased from Cambridge
Isotope Laboratories (Andover, MA, USA); estriol-2,4,17-
d3  (d3-E3), 2-hydroxyestradiol-1,4,16,16,17-d5  (d5-2-
OHE2), 2-methoxyestradiol-1,4,16,16,17-d5  (d5-2-
MeOE2), androstenedione-2,2,4,6,6,16,16-d7 and testos-
terone-16,16,17-d3 were obtained from C/D/N Isotopes
(Pointe-Claire, Quebec, Canada). 16-Epiestriol-2,4,16-d3
(d3-16-epiE3) was purchased from Medical Isotopes (Pel-
ham, NH, USA). All steroid analytical standards have
reported chemical and isotopic purity ≥98%, and were
used without further purification. Dichloromethane and
methanol were obtained from EM Science (Gibbstown,
NJ, USA). Glacial acetic acid and sodium bicarbonate
were purchased from JT Baker (Phillipsburg, NJ, USA)
and sodium hydroxide and sodium acetate were pur-
chased from Fisher Scientific (Fair Lawn, NJ, USA). Ethyl
alcohol was obtained from Pharmco Products (Brook-
field, CT, USA). Formic acid, acetone, dansyl chloride,
and L-ascorbic acid were obtained from Sigma-Aldrich
(St Louis, MO, USA). All chemicals and solvents used in
this study were high performance liquid chromatography
(HPLC) or reagent grade unless otherwise noted.
Preparation of stock and working standard solutions
Stock solutions of steroids and stable isotope labeled ste-
roids were each prepared at 80 μg/ml by dissolving 2 mg
of each estrogen powder in methanol containing 0.1% L-
ascorbic acid to a final volume of 25 ml in a volumetric
flask. Stock solutions were monitored by measuring the
absolute peak height of each steroid using liquid chroma-
tography-mass spectrometry/mass spectrometry (LC-
MS/MS) to verify that no time-dependent degradation of
steroid standards had occurred. The stock solutions are
stable for at least 2 months while stored at -20°C. Work-
ing standard solutions of steroids at 0.32 and 8.0 ng/ml
were prepared by dilutions of the stock solutions with
methanol containing 0.1% L-ascorbic acid.
Sample preparation procedure
To quantitatively measure unconjugated biologically
active estrogen metabolites (EM) and androgens, breast
tissue samples (0.2-0.3 g per patient) were thawed briefly
at room tem perature, minced with scissors, and trans-
ferred into 1.5 ml Eppendorf tubes. A total of 19 AA
patient samples and 20 CAU samples were analyzed. The
tissue was hardened by snap freezing in liquid nitrogen
for 5 min, pulverized and then transferred into a clean
screw-capped glass tube containing 1 ml of ice-cold 12.5
mM NH4HCO3 buffer. The tissue was homogenized on
ice using a Tissue Tearor (Cole-Parmer, Vernon Hills, IL,
USA) at low and high speed in two consecutive 15 s seg-
ments for a total of 30 s, and further sonicated on ice for
five cycles of 10 s pulses with 10 s breaks in between
pulses. Then, 8 ml of ethanol:acetone and 50 μl each of
stable isotope-labeled estrogen and androgen internal
standards (0.32 ng/ml working standard solutions) wereFleming et al. BMC Medicine 2010, 8:27
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added to each tissue homogenate. The mixture was incu-
bated on a rotator at room temperature for 1 h and cen-
trifuged at 3,000 g for 30 min. The ethanol:acetone tissue
extract was transferred to a clean glass tube and dried
under nitrogen gas at 60°C for 1 h (Reacti-Vap III, Pierce,
Rockford, IL, USA). The residue was redissolved in 4 ml
of methanol, vortexed for 1 min, chilled at -80°C for 1 h,
returned to room temperature and then centrifuged at
3,000 g for 20 min. The methanolic phase was transferred
to a clean glass tube and dried under nitrogen gas. The
residue was further redissolved in 100 μl of ethanol and
vortexed briefly. This was followed by the addition of 1.5
ml of 100 mM sodium acetate buffer, pH 4.6 and 5 ml of
dichloromethane to the residue, and incubation at room
temperature on a rotator for 30 min. The extract was
chilled at -80°C for 10 min, returned to room temperature
and centrifuged at 3,000 g  for 20 min. The dichlo-
romethane phase was transferred to a clean tube and
dried. To each dried sample, 32 μl of 0.1 M sodium bicar-
bonate buffer, pH 9.0, and 32 μl of dansyl chloride solu-
tion (1 mg/ml in acetone) were added. After vortexing for
10 s, samples were heated at 70°C (Reacti-Therm III
Heating Module; Pierce) for 10 min to form the EM and
d-EM dansyl derivatives. The dansyl derivatization
method modifies the phenol hydroxyl group of EM and
will not react with testosterone. After derivatization, all
samples were centrifuged at 3,000 g for 20 min, and ana-
lyzed by the capillary LC-ESI-MS/MS.
Capillary liquid chromatography-electrospray ionization 
tandem mass spectrometry analysis (Cap LC-ESI-MS/MS)
Capillary LC-ESI-MS/MS analysis was performed using
an Agilent 1200 series nanoflow LC system (Agilent
Technologies, Palo Alto, CA, USA) coupled to a TSQ
Quantum Ultra triple quadrupole mass spectrometer
(ThermoElectron). The LC separation was carried out on
a 150 mm long × 300 μm internal diameter column
packed with 4 μm Synergi Hydro-RP particles (Phenome-
nex) and maintained at 40°C. A total of 8.0 μl of each
sample was injected onto the column. The mobile phase,
operating at a flow rate of 4.0 μl/min, consisted of metha-
nol as solvent A and 0.1% (v/v) formic acid in water as
solvent B. A linear gradient increasing from 72% to 85%
solvent A in 75 min was employed for the separation. The
MS conditions were source: ESI; ion polarity: positive;
spray voltage: 3,500 V; sheath and auxiliary gas: nitrogen;
sheath gas pressure: 7 arbitrary units; ion transfer capil-
lary temperature, 270°C; scan type: selected reaction
monitoring (SRM); collision gas: argon; collision gas pres-
sure: 1.5 mTorr; scan width: 0.7 u; scan time: 0.50 s; Q1
peak width: 0.70 u full-width half-maximum (FWHM);
Q3 peak width: 0.70 u FWHM. The specific SRM transi-
tions of protonated androgens were: testosterone m/z
289T97 and 109; testosterone-d3 m/z  292T97 and 109;
androstenedione m/z 287T97 and 109; androstenedione-
d7 m/z 287T100 and 113.
Quantitation of tissue estrogens and androgens
Quantitation of tissue estrogens and androgens was car-
ried out using Xcalibur Quan Browser (ThermoElectron).
Briefly, calibration curves for each steroid were con-
structed by plotting non-labeled steroid/stable isotope
labeled steroid peak area ratios obtained from calibration
standards versus amounts of the steroid injected on the
column and fitting these data using linear regression with
1/X weighting. The amounts of steroid in the tissue were
then interpolated using this linear function.
Statistical analysis
Pools of patient samples were necessary to obtain the
required amount of tissue for ECM extraction. When
appropriate, data was evaluated for significance via two-
tailed Student t tests, repeated measures analysis of vari-
ance (ANOVA) with the Bonferroni multiple compari-
sons post hoc analysis, Wilcoxon matched pairs, or Mann-
Whitney tests using GraphPad InStat Software version
3.0b (San Diego, CA, USA). Data was considered signifi-
cant at P < 0.05.
Results
Effects of premenopausal breast fibroblasts on breast 
cancer cell tumorigenicity
It has previously been shown that tumor-derived fibro-
blasts promote, while normal fibroblasts inhibit, the
growth of tumorigenic epithelial cells in vitro and in vivo
[7,27]. Therefore, we first 'humanized' the mouse mam-
mary gland [27] creating a microenvironment with sup-
portive stromal components from either the AA or CAU
breast. Primary breast fibroblasts from age-matched, pre-
menopausal women were isolated [22] and a pool of a
minimum of three patient-derived fibroblasts per group
was injected into mouse abdominal mammary glands. A
different pool of patient fibroblasts was used for each of
three independent humanization experiments. As shown
in Figure 1a, both the AA and CAU fibroblasts equally
humanized the glands, suggesting that the source of the
fibroblasts did not have an effect on the percentage of
growth throughout the glands.
Following humanization, primary metastatic breast
cancer cells (ER-/PR-, as described in Methods) were
injected into the glands. Injection of breast cancer cells
into the humanized glands was repeated in two indepen-
dent experiments using different pools of patient-derived
normal breast fibroblasts; however, the same breast can-
cer patient sample was used specifically to minimize any
confounding effects of the relatively uncharacterized pri-
mary breast cancer cells. For all treatments tested, the
tumor incidence was 100%, with no obvious morphologi-Fleming et al. BMC Medicine 2010, 8:27
http://www.biomedcentral.com/1741-7015/8/27
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cal differences between treatment groups; tumors were
ER-/PR-, undifferentiated invasive carcinomas. Interest-
ingly, glands humanized with CAU fibroblasts repeatedly
developed significantly larger tumors compared to AA
humanized glands (Figure 1b, P < 0.008) suggesting that
either CAU fibroblasts were more permissive to tumori-
genesis, or that AA fibroblasts were more restrictive.
There was no significant difference in the Ki67 prolifera-
tion index at the time of tumor collection (Additional file
1, Figure S1a). Additionally, of the tumors that contained
necrotic regions, there was no significant difference in
the percentage of necrotic area; however, it should be
noted that the significantly larger tumors from glands
humanized with CAU fibroblasts had overall higher levels
of tumors containing necrotic regions compared to the
AA humanized glands (50% vs 33%, Additional file 1, Fig-
ure S1b).
A similar pattern of tumor formation was observed
using T47D, a well characterized, ER+/PR+ human breast
cancer cell line; the cells injected into the glands human-
ized with the CAU fibroblasts had increased tumor vol-
ume (Figure 1c, P < 0.05). The resultant tumors from both
treatment groups were ER+/PR+ by immunohistochemis-
try (data not shown); therefore the hormonal status of the
cells was retained regardless of the source of fibroblasts.
In the presence of fibroblasts derived from the two
groups, differences in tumorigenicity were observed.
Therefore, the expression profiles of 164 ECM molecules
and cytokines were examined using qRT-PCR arrays.
Cytokines were analyzed since components of the
immune system have been reported to modulate the initi-
ation and progression of breast cancer, including metas-
tasis to bone [28-32]. Fibroblasts were expanded in
culture for less than two passages prior to isolation of
total RNA. Different pools of at least three patient sam-
ples per group were used in each of three independent
array experiments (n = 9 AA, n = 10 CAU). A set of ECM
proteins and cytokines was consistently differentially reg-
ulated between the two groups (Additional file 1, Figure
S2a and b, respectively). Array results were validated by
q R T - P C R ;  e x p r e s s i o n  p a t t e r n s  w e r e  o b s e rv e d  n o t  o n l y
using samples from the array analysis, but also with addi-
Figure 1 Tumor formation and extracellular matrix molecules (ECM)/cytokine analyses of premenopausal African-American and Cauca-
sian-American breast fibroblasts. (a) Hematoxylin and eosin (H&E) staining of murine mammary glands humanized with African-American (AA) or 
Caucasian-American (CAU) fibroblasts. (b,c) Humanized murine mammary glands were injected with either primary metastatic breast cancer or T47D 
cells. Data represent mean ± SD of final tumor volume. (d,e) Quantitative real-time PCR analysis: primary human breast fibroblasts were isolated from 
fresh reduction mammoplasty breast tissue. RNA was isolated and analyzed via quantitative real-time PCR. Individual patient samples (n = 18) were 
used to validate array results with newly designed primers to the indicated genes. Data represent fold increase ± standard error of differentially regu-
lated genes. *P < 0.05
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tional randomly chosen, freshly isolated, individual
patient samples (n = 18, Figure 1d, e). As expected, there
was substantial individual patient variation; however, 13
of the 18 genes that were differentially expressed between
the groups in the array analysis were significantly differ-
ent when individual patient samples were analyzed (P <
0.05). Of note, CAU-derived fibroblasts repeatedly exhib-
ited an increase in cytokine expression (Figure 1e and
A d d i t i o n a l  f i l e  1 ,  F i g u r e  S 2 b ) .  T h i s  o b s e r v a t i o n  m a y
explain, in part, the increase in tumor growth observed in
the xenograft experiments (Figure 1b, c). Collectively,
these data suggest that when stromal fibroblasts are con-
fronted with the invasion of tumorigenic breast cells,
genetic variation between the groups differentially
affected tumorigenesis via the production of distinctive
ECM molecules and cytokines.
Effects of premenopausal breast ECM on breast cancer cells 
in vitro
Numerous cell types, in addition to fibroblasts, comprise
the breast microenvironment. To gain further insight into
these multicellular interactions, we analyzed a broader
s p e c t r u m  o f  m o l e c u l e s  w i t h i n  t h e  b r e a s t  b y  i s o l a t i n g
ECM proteins from premenopausal whole breast tissue.
In order to test whether ECM isolated from whole breast
tissue was able to differentially influence breast cancer
cell aggressiveness, we examined cell motility and inva-
siveness using transwell filter assays. Two classes of
breast cancer cell lines were used: ER-/PR- (MDA-MB-
231, SUM159, MCF10Ca1h) and ER+/PR+ (T47D, MCF7,
BT474). These cell lines were chosen for their well char-
acterized phenotype, specifically to limit any confound-
ing effects of uncharacterized primary breast cancer cells.
Cells were overlaid onto one of the three matrices
(adjusted for equal protein concentration) and allowed to
respond to a chemoattractant. Four independent experi-
ments, each with different pools of patient samples (min-
imum of three patient samples per pool), were performed
with each individual experiment repeated in duplicate to
ensure repeatability. Cell invasion through the control
matrix was low for all cell lines tested (Figure 2a). Inter-
estingly, the ability of cells to invade through the ECM
was dependent upon both the cell's hormone receptor
status and the source of the ECM. The ER-/PR- cells were
consistently more invasive when in contact with the AA
ECM. Conversely, all of the ER+/PR+ cell lines tested were
more invasive when in contact with the CAU ECM, sug-
gesting that the invasiveness of cells was enhanced by a
hormone receptor-dependent mechanism in the presence
of CAU ECM. The increased invasiveness may have
occurred through a combinatorial effect of ECM compo-
nents and hormones in the chemoattractant serum. This
potential hormone receptor-dependent stimulus had no
effect on the ER-/PR- cells. In the AA-derived ECM, how-
ever, a hormone-independent mechanism appeared to
further stimulate the invasiveness of the ER-/PR- cells.
S o f t  a g a r  t r a n s f o r m a t i o n  a s s a y s  w e r e  p e r f o r m e d  t o
measure whether the addition of either ECM could differ-
entially influence cell survival under anchorage-indepen-
dent conditions, mimicking changes that occur during
tumorigenesis. Results were similar to those observed
with invasion assays; the AA ECM significantly increased
the number of colonies for the ER-/PR- MDA-MB-231
cells above all other treatments (P < 0.01, Figure 2b). Sim-
ilar results were observed with SUM159 and
MCF10Ca1h cells (Additional file 1, Figure S3). Addition-
ally, the CAU ECM significantly increased colony forma-
Figure 2 Invasion and anchorage-independent growth of breast 
cancer cells in the presence of premenopausal African-American 
or Caucasian-American breast extracellular matrix molecules 
(ECM). (a) Cell invasion through transwell inserts, precoated with 
equal amounts of ECM. Data are representative of four independent 
experiments. (b) Soft agar assays. Cells were stained with nitrobluetet-
razolium before counting after 10 days of growth. The entire dish was 
analyzed and colonies larger than 1 μm in diameter were counted. 
Data represent mean ± standard error of three separate experiments. 
*P < 0.05 **P < 0.01, ***P < 0.001; paired t test. (c) Gelatin zymography. 
ECM was isolated from six pools of 3-7 patients/pool. Results are repre-
sentative of three experiments performed in triplicate. AA = African-
American; CAU = Caucasian-American.
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tion above untreated controls for the ER+/PR+ T47D cell
line (P < 0.05 Figure 2b, similarly for MCF7, ZR75-1, and
BT474 cells; Additional file 1, Figure S3). Thus, the ability
of the cells to survive and proliferate in hostile, anchor-
age-independent conditions appeared dependent upon
both the source of the ECM and the hormonal status of
the cells.
To further analyze the composition of the whole breast
ECM, we assessed its protease activity. The stroma can
act as a reservoir for matrix metalloproteinases (MMPs),
which degrade ECM proteins and process a number of
bioactive molecules. In breast tissue, MMP activity con-
tributes to epithelial cell death, influences tissue remodel-
ing, and has been implicated in cancer invasion and
metastasis [33-35]. Gelatin zymography was employed,
and in multiple experiments the protease activity of at
least two different MMPs was upregulated in the CAU
compared to the AA ECM as determined using gelatin
zymography (representative gel; Figure 2c). When com-
pared to the fibroblast PCR array analysis, there was no
significant increase in MMP expression in the CAU fibro-
blasts compared to the AA, indicating that cells other
than fibroblasts produce MMPs, or that there is increased
stimulation of MMP activity in CAU versus AA ECM.
Effects of ECM on tumorigenicity in vivo
We sought to address whether factors within the breast
E C M ,  r e m o v e d  f r o m  t h e  p h y s i c a l  p r e s e n c e  o f  s t r o m a l
cells, could affect the tumorigenicity of breast cancer cells
in vivo. As described by McDaniel et al. [26], ER-/PR-
MDA-MB-231 or ER+/PR+ T47D breast cancer cells were
mixed with control matrix (Matrigel), AA or CAU ECM
(adjusted for equal protein content) and injected into the
abdominal mammary fat pad of female, athymic nude
mice. No significant difference in tumor efficiency was
observed among the treatments (Figure 3a). However, the
CAU ECM significantly increased tumor growth of the
ER+/PR+ T47D cells compared to either the AA ECM or
control matrix control (Figure 3b; P  < 0.01 and 0.05,
respectively). AA ECM elicited no difference in growth
compared to the control matrix. The resultant T47D
tumors from all treatment groups were ER+; confirming
that hormone status of the cells was retained during
tumor formation (data not shown). Tumor morphology
and percentage necrosis were similar between treat-
ments. These data support the observation that factors
within CAU ECM selectively interact with ER+/PR+ cells
to increase their aggressiveness. The in vitro data demon-
strating enhanced MMP activity and increased cytokine
production in the CAU microenvironment could poten-
tially account for this increase in tumor growth.
Conversely, injecting ER-/PR- MDA-MB-231 cells with
ECM derived from either group gave no selective advan-
tage in tumor growth. Only cells injected with growth
Figure 3 Caucasian-American derived extracellular matrix mole-
cules (ECM) enhances the tumorigenicity of estrogen receptor 
(ER)+/progesterone receptor (PR)+ breast cancer cells. (a) Indicates 
the number of tumors detected per animals injected. (b,c) Data repre-
sent mean ± SD of the final tumor volume of ER+/PR+ (T47D) or ER-/PR- 
(MDA-MB-231) breast cancer cells suspended in the indicated ECM 
and injected into the abdominal mammary gland. (d) Data represent 
mean ± SD of the final tumor volume of MDA-MB-231 breast cancer 
cells suspended in the indicated ECM and injected subcutaneously. AA 
= African-American, CAU = Caucasian-American.
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factor-rich control matrix had significantly increased
final tumor volume (P < 0.05, Figure 3c). To confirm that
the ECM's effect on tumorigenicity was not masked due
to interactions with the host mammary gland, MDA-
MD-231 cells were mixed with control matrix, AA or
CAU ECM, adjusted for equal protein content, and
injected subcutaneously into athymic nude mice. A simi-
lar trend to results obtained from the orthotopic site was
observed. Only cells injected with the control matrix had
substantially larger final tumor volume compared to cells
injected with ECM derived from either group, although
no statistically significant difference was observed
between either ECM (Figure 3d). No significant differ-
ence in tumor latency was observed among the treat-
ments.
Metastasis to the lung and liver was low for all treat-
ments and cell lines tested. Of the 75 lung samples ana-
lyzed, only 18 tested positive for lung metastasis via
pathological examination, immunohistochemical analysis
for human specific COXIV, and qRT-PCR for human β2-
microglobin [26] (Figure 4). No liver metastases were
found by histological examination. Regardless of the cell
type injected, the CAU ECM elicited at least twice the
metastases as AA ECM (Figure 4a). Figure 4c depicts rep-
resentative images of hematoxylin and eosin (H&E)-
stained lungs with overt metastases resulting from the
two cell types, and metastatic cells within the lung were
detected by a human specific COXIV antibody (Figure
4d). No correlation between the size of the primary
tumor and metastasis and no significant difference
between the amount of metastasis and treatment was
observed for all samples analyzed.
Mass spectrometry analysis of the ECM
To determine whether the overall composition of the
ECM differed between premenopausal AAs and CAUs,
breast ECM proteins were intimately examined by LC-
MS/MS. Three independent ECM extraction experi-
ments, using different patient samples for each experi-
ment, with at least three patients per group, (that is, a
total of six individual ECM pools) were analyzed using
LC-MS/MS. Among the 4,288 AA and 4,301 CAU pro-
teins identified, only 1,759 were common between the
groups. Ingenuity pathways analysis (IPA, Ingenuity Sys-
tems, http://www.ingenuity.com) was used for functional
analysis of the results. The majority of the high abun-
dance proteins (≥30 peptide matches) consisted of struc-
tural ECM proteins including numerous collagen species.
These were comparatively similar for either group.
Therefore, we excluded those identified by ≥30 peptides
to focus on those with lower abundance. Additionally,
although it is possible to identify a protein from a single
peptide match after careful inspection of the fragment's
pattern and other characteristics, we excluded these sin-
gle unique peptides and focused our studies on those
above two peptide matches. During analysis, proteins
reported to be exclusively nuclear were excluded as cellu-
lar contamination (23.4% for the AA dataset and 23.0%
for the CAU dataset). In addition to ECM structural pro-
teins, another distinct feature of the microenvironment is
t h e  p r e s e n c e  o f  e x t r a c e l l u l a r  m a t rix  v es i c l es  ( M V)  a n d
exosomes, small sacs secreted from the cell surface which
are enclosed by a membrane structurally similar to that of
the plasma membrane [36]. Molecules located within
MV/exosomes perform diverse functions outside of the
cell including growth factor storage and secretion,
immune regulation, ECM mineralization, and RNA shut-
tling. Interestingly, tumor-associated MV/exosomes have
Figure 4 Caucasian-American extracellular matrix molecules 
(ECM) enhances metastasis to lung. (a) Number of animals positive 
for lung metastasis per animals injected. (b) Ethidium bromide stained 
gel of PCR products; RNA was analyzed by quantitative real-time PCR 
for lung metastasis using human-specific primers to β2 microglobulin. 
C = control human cDNA; L = mouse lung cDNA; NTC = no template 
control. (c) Representative hematoxylin and eosin (H&E)-stained 
mouse lungs with human breast cancer cell metastasis. (d) Immuno-
histochemical detection of metastasized cells with the human-specific 
antibody COXIV (left panels) or corresponding negative controls (right 
panels) in mouse lung. Scale bar = 50 μM. AA = African-American, CAU 
= Caucasian-American.
AA CAU Matrigel
T47D 2/12 5/12 2/11
MDA-MB-231 2/19 4/14 3/18
A
B
C
Positive
 -2 M
NTC
GAPDH
L Negative
T47D   MDA-MD-231  
MDA-MB-
231
T47D  
COXIV Control D
CFleming et al. BMC Medicine 2010, 8:27
http://www.biomedcentral.com/1741-7015/8/27
Page 11 of 21
been shown to contribute to the ability of tumor cells to
escape immune surveillance, degrade ECM to facilitate
invasion, and stimulate angiogenesis [36]. Therefore, no
cytosolic proteins that may have been released into the
ECM by MV/exosomes were excluded. Representative
western blot images of four randomly chosen proteins
were selected for validation of LC-MS/MS analysis with
their corresponding numbers of peptides identified (Fig-
ure 5a, representative spectra shown in Additional file 1,
Figure S4).
Pathways analyses by IPA revealed that the actin
cytoskeleton signaling and the hepatic fibrosis/hepatic
stellate cell activation pathways were only significant for
the AA dataset, based on a strict P value threshold of
0.005 and Benjamini-Hochberg correction (Figure 5b).
Both of these pathways, as well as tight junction signaling
and regulation of actin-based motility by Rho, had
numerous molecules in common including Rho-associ-
ated kinase (ROCK), actin, and several myosins. The sig-
nificant presence of these pathways in only the AA
microenvironment implies unique cytoskeletal signaling
compared to that in CAU.
To further examine differences among datasets, we
analyzed networks created by proteins found exclusively
in the AA or the CAU datasets. The network with the
highest score for the AA dataset contained seven nodes
representing proteins/genes associated with tight junc-
tion signaling and actin cytoskeleton signaling pathway
(Figure 5c). The top network generated by the CAU data-
set contained several other adhesion molecules and the
epidermal growth factor receptor ErbB3, which is known
to promote epithelial cell growth and antiapoptotic sig-
naling. ErbB3 is often overexpressed in human breast
cancers, frequently in conjunction with overexpression of
the proto-oncogene ErbB2/HER2 [37]. Interestingly, the
CAU dataset also contained molecules associated with
the Wnt/β-catenin pathway (Figure 5c), whose dysregula-
tion has been implicated in breast cancer development
and progression [38]. Additional networks for the AA can
CAU datasets can be found in Additional file 1, Figures
S5a-d and S6a-d.
Based on annotations by two manually curated data-
bases (IPA and BIOBASE, http://www.biobase-interna-
tional.com), similar and unique proteins to each dataset,
and their known associations with breast cancer, were
examined. The AA and CAU datasets had 52 common
molecules (Table 1) and 48 and 47 unique proteins,
respectively (Tables 2 and 3). Further functional analyses
of these proteins indicated that the AA dataset were
mainly related to initiation events, including tumorigene-
sis and neoplasia. Alternatively, the proteins unique to
the CAU dataset were primarily involved with tumor
growth or metastasis.
Biologically active estrogen and androgen metabolites
In this study, we show that CAU-derived ECM enhanced
the aggressiveness of ER+/PR+ breast cancer cells, sug-
gesting the microenvironment from which the ECM was
derived may have been exposed to a different hormonal
milieu compared to the AA. Therefore, the hormones
present in the breast microenvironment were quantita-
tively measured by a novel method of LC-MS/MS that
simultaneously extracted and analyzed biologically active
estrogen and androgen metabolites present in whole tis-
sue samples. Breast tissues from fasting, premenopausal
AA and CAU women (median age 32 and 31, respec-
tively; n = 19 AA and 20 CAU) were analyzed. Both
androstenedione and testosterone were detected in all
tissues (Figure 6a, Table 4). Testosterone appeared ele-
vated in the AA breast tissue; however, this observation
was not statistically significant. It is of note that andro-
gens levels were significantly higher in breast tissue com-
pared to estrogens (P < 0.001, Tables 4 and 5), similar to
what has been repeatedly observed in blood. More
importantly, these results shows that the unconjugated
biologically active estrogens found in premenopausal
breast tissues were higher than those reported in blood
[39]. These results warrant further study given the role of
estrogen metabolites in tumorigenesis.
Of the 15 estrogen metabolites measured, only 5 were
readily detectable as intrinsic components of breast tis-
sue: estrone, estradiol, estriol, 2-methoxyestrone, and 2-
hydroxyestradiol (Table 5). Estradiol, estriol and 2-meth-
oxyestrone were significantly higher in the CAU breast
tissue (P < 0.005), which was unanticipated given that
previous studies have shown that premenopausal AA
women have higher plasma concentrations of estrogens
[40,41]. Additionally, tissue levels of 2-hydroxyestradiol, a
known carcinogen, were also detected in two patient
samples, one from each group (Table 5, mean pg/g = 18.1
± 4.7 for AA and 29.8 ± 14.9 for CAU). The data pre-
sented here advocate for a more intensive analysis of the
hormonal milieu of the breast microenvironment in addi-
tion to plasma levels, since local hormones are directly
responsible for mediating cellular function and influence
tumorigenesis.
Discussion
This report is the first to analyze differences in the nor-
mal breast microenvironment of premenopausal women,
and to show fundamental differences in the ability of
breast ECM to influence the aggressiveness and tumori-
genicity of breast cancer cells. The comprehensive LC-
MS/MS identification of whole tissue hormone metabo-
lites, as well as unique ECM proteins between the AA and
CAU women, offers a novel insight into the intricacy of
the breast microenvironment.Fleming et al. BMC Medicine 2010, 8:27
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One limitation of this study, which must be addressed,
is the lack of descriptive clinical data on the breast tissue
isolated from the reduction mammoplasty patients. The
tissue collected for fibroblast and whole breast tissue
ECM isolation were considered pathological medical
waste; therefore, informative clinical data including par-
ity, body mass index, breast density, oral contraceptive
use, phase of menstrual cycle were not available. Whether
these important factors potentially had confounding
effects on the observed results is regrettably unknown. In
attempts to limit these effects, each experiment con-
tained multiple replicates, and was repeated using as
Figure 5 Proteomic analysis of African-American and Caucasian-American breast extracellular matrix molecules (ECM). (a) Western blot of 
proteins identified by mass spectrometry with corresponding identified peptides. (b) Datasets of proteins unique to African-American or Caucasian-
American ECM grouped according to significant association to canonical pathways. B-H = Benjamini-Hochberg. (c) In silico analysis of proteins: top 
signaling network of proteins unique to the African-American (left) or Caucasian-American (right) datasets. AA = African-American, CAU = Caucasian-
American.
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Table 1: Proteins found in both African-American and Caucasian-American datasets reported to be involved in breast 
cancer, as annotated by Ingenuity Systems or BIOBASE.
Symbol Entrez gene name Location Entrez gene ID
ABCC4 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 Plasma membrane 10257
ACTA2 Actin, alpha 2, smooth muscle, aorta Cytoplasm 59
ACTB Actin, beta Cytoplasm 60
ADAMTS15 ADAM metallopeptidase with thrombospondin type 1 motif, 15 Extracellular space 170689
ADRA1B Adrenergic, alpha-1B-, receptor Plasma membrane 147
ANXA2 Annexin A2 Plasma membrane 302
APOB Apolipoprotein B (including Ag(x) antigen) Extracellular space 338
APOD Apolipoprotein D Extracellular space 347
ATP5B ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide Cytoplasm 506
AXL AXL receptor tyrosine kinase Plasma membrane 558
C3 Complement component 3 Extracellular space 718
CAV1 Caveolin 1, caveolae protein, 22 kDa Plasma membrane 857
CNR2 Cannabinoid receptor 2 (macrophage) Plasma membrane 1269
COL18A1 Collagen, type XVIII, alpha 1 Extracellular space 80781
CYP2C9 Cytochrome P450, family 2, subfamily C, polypeptide 9 Cytoplasm 1559
DCD Dermcidin Extracellular space 117159
DSP Desmoplakin Plasma membrane 1832
FES Feline sarcoma oncogene Cytoplasm 2242
FN1 Fibronectin 1 Plasma membrane 2335
GART Phosphoribosylglycinamide formyltransferase/synthetase, Cytoplasm 2618
GFRA1 GDNF family receptor alpha 1 Plasma membrane 2674
HSPA5 Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) Cytoplasm 3309
HSPG2 Heparan sulfate proteoglycan 2 Plasma membrane 3339
IGF2R Insulin-like growth factor 2 receptor Plasma membrane 3482
IGKC Immunoglobulin kappa constant Extracellular space 3514
ITGA2 Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) Plasma membrane 3673
JUP Junction plakoglobin Plasma membrane 3728
LAMA3 Laminin, alpha 3 Extracellular space 3909
LDHA Lactate dehydrogenase A Cytoplasm 3939
LEPR Leptin receptor Plasma membrane 3953
LGALS1 Lectin, galactoside-binding, soluble, 1 Extracellular space 3956
MAGED1 Melanoma antigen family D, 1 Plasma membrane 9500
MAP3K4 Mitogen-activated protein kinase kinase kinase 4 Cytoplasm 4216
MUC16 Mucin 16, cell surface associated Extracellular space 94025
MUC5AC Mucin 5AC, oligomeric mucus/gel-forming Extracellular space 4586
NF1 Neurofibromin 1 Cytoplasm 4763
PCM1 Pericentriolar material 1 Cytoplasm 5108
POSTN Periostin, osteoblast specific factor Extracellular space 10631
PRDX3 Peroxiredoxin 3 Cytoplasm 10935
PRKCG Protein kinase C, gamma Cytoplasm 5582
PRLR Prolactin receptor Plasma membrane 5618
PTN Pleiotrophin Extracellular space 5764
PTPN13 Protein tyrosine phosphatase, non-receptor type 13 Cytoplasm 5783
PXDN Peroxidasin homolog (Drosophila) Unknown 7837
SERPINA1 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin) 1 Extracellular space 5265
SLC16A3 Solute carrier family 16, member 3 (monocarboxylic acid transporter 4) Plasma membrane 9123
SLC19A1 Solute carrier family 19 (folate transporter), member 1 Plasma membrane 6573
TES Testis derived transcript (3 LIM domains) Plasma membrane 26136
TNC Tenascin C Extracellular space 3371
TUBA1A Tubulin, alpha 1a Cytoplasm 7846
VCL Vinculin Plasma membrane 7414
VTN Vitronectin Extracellular space 7448Fleming et al. BMC Medicine 2010, 8:27
http://www.biomedcentral.com/1741-7015/8/27
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Table 2: Proteins found unique to the African-American dataset that are reported to be involved in breast cancer, as 
annotated by Ingenuity Systems or BIOBASE.
Symbol Entrez gene name Location Entrez gene ID
ADAM12 ADAM metallopeptidase domain 12 Plasma membrane 8038
ADRA2C Adrene gic, alpha-2C-, receptor Plasma membrane 152
AKR1C1 Aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1) Cytoplasm 1645
ANK1 Ankyrin 1, erythrocytic Plasma membrane 286
ANXA1 Annexin A1 Plasma membrane 301
ANXA5 Annexin A5 Plasma membrane 308
BCAS1 Breast carcinoma amplified sequence 1 Unknown 8537
CAMKK1 Calcium/calmodulin-dependent protein kinase kinase 1, alpha Cytoplasm 84254
CANX Calnexin Cytoplasm 821
CASP1 Caspase 1, apoptosis-related cysteine peptidase (interleukin 1, convertase Cytoplasm 834
CD69 CD69 molecule Plasma membrane 969
CDH11 Cadherin 11, type 2, OB-cadherin (osteoblast) Plasma membrane 1009
CDR2 Cerebellar degeneration-related protein 2, 62 kDa Cytoplasm 1039
CTSD Cathepsin D Cytoplasm 1509
DAB2 Disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila) Plasma membrane 1601
DECR1 2,4-Dienoyl CoA reductase 1, mitochondrial Cytoplasm 1666
DFNA5 Deafness, autosomal dominant 5 Unknown 1687
DLC1 Deleted in liver cancer 1 Cytoplasm 10395
EDNRB Endothelin receptor type B Plasma membrane 1910
EEF1A1 Eukaryotic translation elongation factor 1 alpha 1 Cytoplasm 1915
ERBB4 V-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) Plasma membrane 2066
FBLN1 Fibulin 1 Extracellular space 2192
GAPDH Glyceraldehyde-3-phosphate dehydrogenase Cytoplasm 2597
GRIN2D Glutamate receptor, ionotropic, N-methyl D-aspartate 2D Plasma membrane 2906
GSN Gelsolin (amyloidosis, Finnish type) Extracellular space 2934
HSPB1 Heat shock 27 kDa protein 1 Cytoplasm 3315
IGF1R Insulin-like growth factor 1 receptor Plasma membrane 3480
KDR Kinase insert domain receptor (a type III receptor tyrosine kinase) Plasma membrane 3791
LTF Lactotransferrin Extracellular space 4057
MET Met proto-oncogene (hepatocyte growth factor receptor) Plasma membrane 4233
MMP14 Matrix metallopeptidase 14 (membrane-inserted) Extracellular space 4323
MUC6 Mucin 6, oligomeric mucus/gel-forming Extracellular space 4588
NLRP1 NLR family, pyrin domain containing 1 Cytoplasm 22861
ORM1 Orosomucoid 1 Extracellular space 5004
PDGFRB Platelet-derived growth factor receptor, beta polypeptide Plasma membrane 5159
PLXNA1 Plexin A1 Plasma membrane 5361
POR P450 (cytochrome) oxidoreductase Cytoplasm 5447
PTPRG Protein tyrosine phosphatase, receptor type, G Plasma membrane 5793
ROCK1 Rho-associated, coiled-coil containing protein kinase 1 Cytoplasm 6093
S100A9 S100 calcium binding protein A9 Cytoplasm 6280
SERPINA3 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase), member 3 Extracellular space 12
SERPINB5 Serpin peptidase inhibitor, clade B (ovalbumin), member 5 Extracellular space 5268
SOD1 Superoxide dismutase 1, soluble Cytoplasm 6647
SOD2 Superoxide dismutase 2, mitochondrial Cytoplasm 6648
SYK Spleen tyrosine kinase Cytoplasm 6850
TAGLN Transgelin Cytoplasm 6876
TJP1 Tight junction protein 1 (zona occludens 1) Plasma membrane 7082
TXNRD1 Thioredoxin reductase 1 Cytoplasm 7296Fleming et al. BMC Medicine 2010, 8:27
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Table 3: Proteins found unique to the Caucasian-American dataset that are reported to be involved in breast cancer, as 
annotated by Ingenuity Systems or BIOBASE.
Symbol Entrez gene name Location Entrez 
gene ID
ABCC5 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 Plasma membrane 10057
ACE Angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Plasma membrane 1636
BCAR3 Breast cancer anti-estrogen resistance 3 Cytoplasm 8412
CDON Cdon homolog (mouse) Plasma membrane 50937
CLCA2 CLCA family member 2, chloride channel regulator Plasma membrane 9635
CSF1R Colony stimulating factor 1 receptor Plasma membrane 1436
CTGF Connective tissue growth factor Extracellular space 1490
DAPK1 Death-associated protein kinase 1 Cytoplasm 1612
DLG5 Discs, large homolog 5 (Drosophila) Plasma membrane 9231
ERBB3 V-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) Plasma membrane 2065
FRZB Frizzled-related protein Extracellular space 2487
GREB1 GREB1 protein Cytoplasm 9687
HGF Hepatocyte growth factor (hepapoietin A; scatter factor) Extracellular space 3082
HPN Hepsin (transmembrane protease, serine 1) Plasma membrane 3249
HSPA8 Heat shock 70 kDa protein 8 Cytoplasm 3312
IL17RB Interleukin 17 receptor B Plasma membrane 55540
IRS2 Insulin receptor substrate 2 Cytoplasm 8660
ITGA6 Integrin, alpha 6 Plasma membrane 3655
KCNH1 Potassium voltage-gated channel, subfamily H (eag-related), member 1 Plasma membrane 3756
KISS1 KiSS-1 metastasis-suppressor Cytoplasm 3814
LGALS3 Lectin, galactoside-binding, soluble, 3 Extracellular space 3958
LPA Lipoprotein, Lp(a) Extracellular space 4018
LPHN2 Latrophilin 2 Plasma membrane 23266
LTA Lymphotoxin alpha (TNF superfamily, member 1) Extracellular space 4049
MAP2K5 Mitogen-activated protein kinase kinase 5 Cytoplasm 5607
MINK1 Misshapen-like kinase 1 (zebrafish) Cytoplasm 50488
NOS3 Nitric oxide synthase 3 (endothelial cell) Cytoplasm 4846
NOTCH4 Notch homolog 4 (Drosophila) Plasma membrane 4855
NRG1 Neuregulin 1 Extracellular space 3084
OAS3 2'-5'-oligoadenylate synthetase 3, 100 kDa Cytoplasm 4940
P4HB Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), beta polypeptide Cytoplasm 5034
PKD1 Polycystic kidney disease 1 (autosomal dominant) Plasma membrane 5310
PLG Plasminogen Extracellular space 5340
PTPRF Protein tyrosine phosphatase, receptor type, F Plasma membrane 5792
RASA1 RAS p21 protein activator (GTPase activating protein) 1 Cytoplasm 5921
SERPINI2 Serpin peptidase inhibitor, clade I (pancpin), member 2 Extracellular space 5276
SH3RF1 SH3 domain containing ring finger 1 Cytoplasm 57630
SOCS1 Suppressor of cytokine signaling 1 Cytoplasm 8651
TBC1D9 TBC1 domain family, member 9 (with GRAM domain) Plasma membrane 23158
TGFBR2 Transforming growth factor, beta receptor II (70/80 kDa) Plasma membrane 7048
TIAM1 T-cell lymphoma invasion and metastasis 1 Cytoplasm 7074
TNN Tenascin N Plasma membrane 63923
TPI1 Triosephosphate isomerase 1 Cytoplasm 7167
VWF von Willebrand factor Extracellular space 7450
WISP2 WNT1 inducible signaling pathway protein 2 Extracellular space 8839
WNT11 Wingless-type MMTV integration site family, member 11 Extracellular space 7481
YWHAZ Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide Cytoplasm 7534Fleming et al. BMC Medicine 2010, 8:27
http://www.biomedcentral.com/1741-7015/8/27
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Table 4: Unconjugated biologically active androgens (pg/g) detected in breast tissue.
Sample ID Wet weight (g) Androstenedione Testosterone Total
AA1 0.307 2,546.9 428.5 2,975.4
AA2 0.293 2,393.9 422.5 2,816.4
AA3 0.305 673.7 20,433.2 21,106.9
AA4 0.290 2,922.5 628.7 3,551.2
AA6 0.375 1,196.0 419.9 1,615.9
AA7 0.317 6,634.4 872.9 7,507.3
AA8 0.324 443.1 152.6 595.7
AA10 0.272 2,748.0 470.5 3,218.6
AA11 0.249 844.5 224.6 1,069.2
AA12 0.270 1,099.8 184.6 1,284.4
AA13 0.269 601.8 120.1 721.9
AA14 0.289 2,890.2 373.8 3,264.0
AA15 0.299 4,678.6 664.0 5,342.6
AA16 0.345 832.0 184.3 1,016.3
AA17 0.298 1,314.9 203.8 1,518.7
AA18 0.299 562.4 667.5 1,229.9
AA19 0.263 910.0 184.4 1,094.4
AA5 0.348 1,588.9 227.4 1,816.3
Mean 0.303 1,937.9 1,492.4 3,430.3
SD 0.033 1,634.7 4,731.9 4,756.7
SEM 0.008 385.3 1,115.3 1,121.2
CA1 0.267 5,927.3 1,103.9 7,031.2
CA2 0.283 1,904.7 178.2 2,082.9
CA3 0.268 2,390.2 424.8 2,815.0
CA4 0.328 311.5 141.4 452.9
CA5 0.260 879.7 740.8 1,620.5
CA6 0.294 962.5 211.5 1,173.9
CA7 0.295 1,425.8 155.2 1,581.0
CA8 0.260 515.2 180.6 695.8
CA9 0.255 1,993.1 536.8 2,529.9
CA10 0.324 710.3 588.4 1,298.7
CA12 0.305 1,448.6 284.1 1,732.7
CA14 0.208 1,540.4 361.3 1,901.8
CA15 0.258 2,997.8 437.5 3,435.3
CA16 0.319 1,068.2 4,855.9 5,924.1
CA17 0.310 1,062.6 295.0 1,357.6
CA18 0.297 3,515.1 343.6 3,858.7
CA19 0.323 3,906.8 165.4 4,072.2
CA20 0.312 3,070.7 95.9 3,166.6
Mean 0.29 1,979.47 616.69 2,596.16
SD 0.03 1,440.86 1,087.75 1,757.64
SEM 0.01 339.61 256.38 414.28
SEM = standard error of the mean.
many different pools of patient samples feasible. A total
of 50 CAU and 53 AA samples were used in the different
analyses. However, the possibility remains that inherent
factors from the tissue source could remain. Further-
more, we obtained samples from southern, eastern, and
midwestern US, which may help eliminate the effects of
socioeconomic factors if the samples had been obtained
from one small geographical region. DeterminingFleming et al. BMC Medicine 2010, 8:27
http://www.biomedcentral.com/1741-7015/8/27
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Table 5: Unconjugated biologically active estrogens (pg/g) detected in breast tissue.
Sample ID Wet 
weight (g)
16KE2 E3 16aE1 16epiE3 17epiE3 3ME1 2ME1 4ME1 2ME2 E1 4ME2 E2 2OHE1 2OHE2 4OHE1 Total 
(pg/g)
AA1 0.307 ND 3.92 ND ND ND ND 24.34 ND ND 459.21 ND 138.15 ND ND ND 625.63
AA2 0.293 ND 6.86 ND ND ND ND 4.21 ND ND 456.38 ND 210.90 ND 21.41 ND 699.77
AA3 0.305 ND 6.44 ND ND ND ND 4.33 ND ND 26.35 ND 15.42 ND ND ND 52.55
AA4 0.290 ND 7.33 ND ND ND ND 4.23 ND ND 314.41 ND 105.14 ND 14.77 ND 445.87
AA5 0.348 ND 24.88 ND ND ND ND 16.47 ND ND 313.31 ND 69.34 ND ND ND 424.00
AA6 0.375 ND 18.97 ND ND ND ND NF ND ND 106.18 ND 34.39 ND ND ND 159.54
AA7 0.317 ND 43.72 ND ND ND ND 5.49 ND ND 728.23 ND 243.73 ND ND ND 1,021.17
AA8 0.324 ND 4.38 ND ND ND ND 14.50 ND ND 248.02 ND 45.20 ND ND ND 312.10
AA10 0.272 ND 11.02 ND ND ND ND NF ND ND 284.35 ND 103.53 ND ND ND 398.89
AA11 0.249 ND 16.88 ND ND ND ND 5.28 ND ND 70.04 ND 44.63 ND ND ND 136.83
AA12 0.270 ND 16.01 ND ND ND ND 22.83 ND ND 248.26 ND 38.55 ND ND ND 325.65
AA13 0.269 ND 16.53 ND ND ND ND 4.26 ND ND 20.14 ND 4.47 ND ND ND 45.41
AA14 0.289 ND 28.49 ND ND ND ND 1.30 ND ND 210.22 ND 59.68 ND ND ND 299.68
AA15 0.299 ND 4.07 ND ND ND ND 20.11 ND ND 351.99 ND 141.77 ND ND ND 517.93
AA16 0.345 ND 6.28 ND ND ND ND 1.69 ND ND 44.37 ND 19.59 ND ND ND 71.94
AA17 0.298 ND 33.88 ND ND ND ND 14.32 ND ND 135.21 ND 17.07 ND ND ND 200.47
AA18 0.299 ND 19.29 ND ND ND ND 2.69 ND ND 34.00 ND 1.21 ND ND ND 57.19
AA19 0.263 ND 2.51 ND ND ND ND 5.32 ND ND 171.89 ND 36.87 ND ND ND 216.60
Mean 0.30 15.08 9.46 234.59 73.87 18.09 333.96
SD 0.03 11.64 7.93 187.28 70.29 4.69 261.24
SEM 0.01 2.74 1.87 44.14 16.57 1.11 61.57
CA1 0.267 ND 39.42 ND ND ND ND 39.50 ND ND 350.35 ND 120.01 ND ND ND 549.27
CA2 0.283 ND 16.31 ND ND ND ND 5.35 ND ND 118.71 ND 385.77 ND ND ND 526.13
CA3 0.268 ND 37.05 ND ND ND ND 44.14 ND ND 131.34 ND 146.55 ND ND ND 359.08
CA4 0.328 ND 12.71 ND ND ND ND 38.10 ND ND 221.08 ND 615.33 ND ND ND 887.22
CA5 0.260 ND 6.87 ND ND ND ND 27.61 ND ND 50.04 ND 100.53 ND ND ND 185.05
CA6 0.294 ND 22.91 ND ND ND ND 23.82 ND ND 85.70 ND 36.74 ND 19.25 ND 188.41
CA7 0.295 ND 49.19 ND ND ND ND NF ND ND 98.10 ND 32.98 ND 40.37 ND 220.63
CA8 0.260 ND 23.83 ND ND ND ND 10.86 ND ND 34.00 ND 128.15 ND ND ND 196.85
CA9 0.255 ND 26.86 ND ND ND ND 54.25 ND ND 266.36 ND 153.19 ND ND ND 500.66
CA10 0.324 ND 15.30 ND ND ND ND 10.95 ND ND 61.18 ND 79.33 ND ND ND 166.76
CA12 0.305 ND 45.37 ND ND ND ND 16.33 ND ND 158.05 ND 106.95 ND ND ND 326.70
CA14 0.208 ND 67.15 ND ND ND ND 25.67 ND ND 337.20 ND 106.82 ND ND ND 536.84
CA15 0.258 ND 25.99 ND ND ND ND 31.21 ND ND 167.88 ND 64.90 ND ND ND 289.98
CA16 0.319 ND 32.34 ND ND ND ND 26.20 ND ND 351.61 ND 163.97 ND ND ND 574.12
CA17 0.310 ND 17.61 ND ND ND ND 5.73 ND ND 135.22 ND 69.24 ND ND ND 227.80
CA18 0.297 ND 101.07 ND ND ND ND 63.23 ND ND 174.84 ND 66.20 ND ND ND 405.34
CA19 0.323 ND 9.35 ND ND ND ND 17.33 ND ND 63.77 ND 46.59 ND ND ND 137.03
CA20 0.312 ND 19.01 ND ND ND ND 26.06 ND ND 78.28 ND 57.49 ND ND ND 180.83
Mean 0.29 31.57 27.43 160.21 137.82 29.81 358.82
SD 0.03 23.25 16.40 104.55 143.23 14.94 201.33
SEM 0.01 5.48 3.87 24.64 33.76 3.52 47.45
ND = not detected; SEM = standard error of the mean.
whether clinical factors, or genetics, or a combination of
the two, systematically relate as to why AAs develop a
more aggressive cancer is not the purpose of this study.
The objective of this study was not to determine how
these discrepancies develop, but rather to use the infor-
mation obtained to study their influence on breast cancer
behavior. In addition, patient samples were pooled in
order to obtain sufficient amount of ECM to performFleming et al. BMC Medicine 2010, 8:27
http://www.biomedcentral.com/1741-7015/8/27
Page 18 of 21
these experiments. Although pooled samples are not
ideal, a consistent pattern was observed with all results
obtained even in this potentially confounding situation.
Since no patient sample could be used twice, this suggests
that our conclusions were not skewed by any single sam-
ple. Future studies to determine specific components in
ECM responsible for these effects will require examina-
tion of individual tissues, if enough material becomes
available from a single patient. Overall, the results pre-
sented provide valuable data for further investigation into
the role of the microenvironment in cancer disparities,
and potentially as a basis for future studies investigating
factors such as parity and phase of menstrual cycle on
breast cancer cell behavior.
Collectively, the data presented in this report suggest
that the AA breast microenvironment is less permissive
of tumor growth compared to the CAU breast microenvi-
ronment. Therefore, it is not surprising that only the
more aggressive cells are able to survive and proliferate
unrestrictedly in the suppressive microenvironment of
AA breast tissue. The comparatively suppressive effects
of the AA ECM may arise from both a physical restriction
due to the types of structural material present in the
ECM, and chemically from the signals present, or absent,
in the microenvironment. Numerous reports have indi-
cated that the spatial organization and composition of the
ECM influence mammary cell behavior, and that altera-
tions in ECM receptor expression facilitate malignant
transformation [42].
The premenopausal stroma is not a static compart-
ment; proliferation in the breast varies with the men-
strual cycle, which requires the expansion and deposition
of new ECM [43]. Increased deposition of molecules such
as collagen can alter the ECM biophysical properties and
increase extracellular cellular tension. ECM composition
and rigidity modulate cell-ECM interactions and have a
significant impact on cell functions. Indeed, mammary
epithelial cells cultured on matrices with increased stiff-
ness have disrupted cell-cell junctions, increased prolifer-
ation, perturbed endogenous basement membrane
assembly, and a dedifferentiated phenotype [44,45]. The
development of breast cancer is characterized by the loss
of tissue organization and an increase in tissue rigidity,
suggesting that aberrant tension may facilitate the acqui-
sition of a malignant phenotype [45]. For example, pri-
mary mammary epithelial cells cultured on floating
collagen gels were shown to differentiate in response to
lactogenic hormones only when plated on collagen gels
with reduced tensional forces. When plated on gels with
increased tension, the extracellular forces promoted cell
Figure 6 Detection of estrogens and androgens in whole breast tissue. Data represent the mean (n = 18 African-American (AA) and 20 Cauca-
sian-American (CAU)) of biologically active androgens (a) or estrogens (b) ± standard error analyzed via chromatography-tandem mass spectrometry. 
*P < 0.005; Wilcoxon matched pairs or paired t test, accordingly.
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spreading, increased MMP activity, and inhibited acini
formation and cellular differentiation [46]. Interestingly,
triple-negative tumors (ER-/PR- and lacking HER2 ampli-
fication) are composed of undifferentiated cells, poten-
tially resulting from a small, localized area of matrix
stiffness and high tension. Paszek et al. demonstrated that
matrix stiffness promotes tumor-like behavior in mam-
mary cells, and blocking integrin-dependent cell contrac-
tility reverted the malignant phenotype in culture [44].
Thus, if the premenopausal AA microenvironment is
comparatively more restrictive in its composition/organi-
zation, as our data suggests, this may predispose AAs to
triple-negative breast cancer. Further studies on this topic
are warranted.
The use of a selective pressure to isolate a more tumori-
genic cell is often used in studies seeking to identify the
progenitor tumor-initiating cells (cancer stem cell) via
culturing the cells in non-adherent conditions [47]. The
rationale driving this culture system is that only the pro-
genitor tumor-initiating cells are able to survive and self-
renew when contact with the ECM is disrupted, whereas
differentiated, non-tumor initiating cells experience anoi-
kis and die [48]. Potentially a similar mechanism of selec-
tive pressure is actively selecting for the more aggressive
cancer cell in the restrictive premenopausal AA microen-
vironment.
It is noteworthy that the invasiveness, tumorigenicity,
and metastases of the ER+/PR+ cells were enhanced in the
presence of the CAU ECM. It has been similarly shown
that breast cancer cell proliferation, in response to andro-
gens, was dependent upon both the ER status of the cell
and signals from the ECM. Specifically, ER+ MCF7 cells
proliferated in the presence of dihydrotestosterone
(DHT) by an ERα-dependent mechanism; however,
MDA-MB-231 cells responded to DHT by an ER-inde-
pendent, αvβ3 integrin pathway [49]. Additional estrogen
and ECM/integrin interactions related to tumorigenesis
have been reported. Hypoxia-inducible factor 1α (HIF-
1α), a transcription factor which is overexpressed in the
majority of human carcinomas and controls central
metastasis-associated pathways, was shown to increase
anchorage-independent growth by downregulation of the
α5 integrin [50]. Anchorage independent growth and
decreased α5 integrin levels were reverted by treatment
with the estrogen metabolite, 2-methoxyestradiol, a
known pharmacological inhibitor of HIF-1α.
This is the first report to simultaneously analyze the
biologically-active estrogens and androgens from each
patient in whole breast tissue via LC-MS/MS; previous
studies measured blood and urine levels. This method
offers a more intimate analysis of the local hormone
milieu of the breast microenvironment, compared to
measuring circulating levels of hormones. Indeed, it is
now well known that the local synthesis from the stromal
cells dramatically contributes to the growth, function,
and tumorigenesis of ER/PR positive and negative breast
cells [51-53]. BRCA1 tumors, the majority of which are
ER-, have been effectively prevented by ovariectomy [54].
Furthermore, it is proposed that the increased risk of
breast cancer following pregnancy is due to high levels of
estrogen and other pregnancy associated hormones that
promote the growth of already initiated target cell popu-
lations [55]. Interestingly, the majority of breast cancers
that develop during this time are ER-/PR- suggesting that
hormones affect the local microenvironment.
Different estrogen metabolites have been reported to
act as either carcinogens or to protect from tumorigene-
sis, although their precise mechanisms are yet to be fully
defined. The production of 16α-hydroxyestrone has been
hypothesized to initiate breast cell transformation by act-
ing as an estrogen agonist, increasing cellular prolifera-
tion and generating reactive oxygen species thereby
causing DNA damage [56]. Conversely, 2-hydroxyestra-
diol has been shown to possess estrogen antagonist prop-
erties in vivo [56]. In this report, the primary estradiol/
estrone metabolites detected were estriol, a product of
the 16α-hydroxylation pathway, and 2-methoxyestrone, a
product of the 2-hydroxylation pathway. It is of note that
these two metabolites appear to be equally balanced in
the tissue, as it has been shown that alterations in the
ratio of C2/C16 estradiol/estrone hydroxylation can lead
to anchorage-independent growth and tumorigenesis
[57]. Analysis of these hormone metabolites in breast tis-
sue, as opposed to circulating levels, could potentially be
used for early detection of breast cancer in high-risk
patients.
Our understanding of the interactions between the
numerous cell types within breast, especially during tum-
origenesis, still remains vague owing to the complexity of
physical and chemical communication, and inherent dif-
ferences between patients and their resultant types of
cancer. However, apart from individual patient differ-
ences, there is indisputable evidence that breast carcino-
mas in premenopausal AA women tend to be triple
negative and highly metastatic compared to breast carci-
nomas in CAU women. Identifying the initiating factors
in the development of triple-negative breast cancer in
premenopausal AA women will fill a gap of knowledge in
breast cancer research. Why these women should have an
increased incidence of this disease compared to other
racial groups remains elusive.
Conclusions
This report details the importance of the normal breast
microenvironment on breast cancer cell behavior, an
essential step in the investigation of the etiology of breast
cancer. The data presented characterize the composition
of normal premenopausal breast tissue and provides dataFleming et al. BMC Medicine 2010, 8:27
http://www.biomedcentral.com/1741-7015/8/27
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for further investigation into the role of the microenvi-
ronment in cancer disparities.
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